Abstract 9655: Risk Factors and Clinical Outcomes Associated with Gastrointestinal Bleeding Among Amyloidosis Patients

Abstract

Background: Amyloidosis is the deposition of abnormal localized or systemic extracellular proteins in tissues. Upper and lower gastrointestinal (GI) bleeds are a known complication of amyloidosis. We assess risk factors and outcomes associated with GI bleeding in hospitalized patients with amyloidosis. Methods: This retrospective study used data from the 2015-2018 National Inpatient Sample Database to determine the prevalence of GI bleeding and risk factors associated with GI bleeding in patients with amyloidosis based on ICD-9 codes. Demographics included age, race, and gender. Comorbidities included hypertension, diabetes, heart failure, renal failure and coronary artery disease. Outcomes included death, and length of stay (LOS). The weight adjusted prevalence of GI bleed was estimated using binomial model with 95% confidence interval (CI) and the association was summarized with weighted relative risk (RR) regression analyses. Results: This study included 34,894 records of patients with amyloidosis, of which 1,022 had GI bleed. Amyloidosis patients with GI bleeds were older than patients without GI bleeds (63.86 vs. 60.94 years, p= <.0001 and more likely to be male (51.85 vs. 42.04 p= <.0001) and had more renal failure, diabetes, heart failure, and liver disease. Amyloidosis patients with GI bleed had significantly higher length of stay (2.93 [95% CI 2.75-3.12]) and higher mortality than those without GI bleeding (RR 2.64 [95% CI 2.17 - 3.22], p <0.0001). Conclusion: Among patients with amyloidosis, GI bleeding was more common in males, older individuals, and those with renal failure, diabetes, heart failure, and liver disease. Patients with amyloidosis and GI bleeds had significantly higher mortality with longer LOS than those without GI bleeding. Patients with amyloidosis with GI bleeding should be targeted for aggressive therapies to improve outcomes.